Oslo Cancer Cluster Innovation Park: A powerhouse for the development of cancer treatments

Innovation Park and the surrounding buildings

This article was originally published in Norwegian on Altomdinhelse.no by Mediaplanet, and was written by Jónas Einarsson, CEO of Radforsk and initiator of Oslo Cancer Cluster, Oslo Cancer Cluster Incubator and Oslo Cancer Cluster Innovation Park. 

We wish to expand Oslo Cancer Cluster Innovation Park with close to 50 000 square metres the next five to seven years. The goal is to develop even better cancer treatments to improve the lives of cancer patients, in close collaboration with the ecosystem around the park.

On 24 August 2015, the Norwegian Prime Minister Erna Solberg opened Oslo Cancer Cluster Innovation Park. In her speech, she said: “Oslo Cancer Cluster Innovation Park will fulfil an important role in the development of the cancer treatments of the future.”

That moment was the starting point for a unique collaboration between cancer researchers, clinicians, teachers, students, business developers and numerous other professions that are needed to develop tomorrow’s cancer treatments.

All of us that work here share a common vision: Oslo Cancer Cluster Innovation Park and the environment around the Norwegian Radium Hospital and the Institute for Cancer Research (Oslo University Hospital) should be an international powerhouse for the development of cancer treatments.

The beginning of a success story

Five years after the opening, we are still fulfilling that vision every day. I would even go so far as to say that we have contributed to a success story:

  • Oslo Cancer Cluster Incubator houses nine start-up companies today, and we are working closely with seven other companies that are located other places due to limited space.
  • The 24 private and public tenants of Oslo Cancer Cluster Innovation Park want more space, since their operations are ever growing.
  • Ullern Upper Secondary School is one of the most sought-after schools in Oslo and the number of students is ever increasing. The students are offered the opportunity to participate in the school collaboration with Oslo Cancer Cluster, to educate the researchers and entrepreneurs of tomorrow. In the autumn of 2019, the researcher programme was initiated at Ullern, which is a unique opportunity for students in Oslo to specialise in biomedical subjects.

Many developments planned

Everything mentioned above is only what is happening inside the Innovation Park. In the nearby area, there are many unique developments that will change the treatment of cancer patients in coming years:

  • In 2023, the new clinic building of the Norwegian Radium Hospital and its specialised proton centre will open.
  • The Institute for Cancer Research is being developed further under the proficient management of Professor Kjetil Taskén. The talented researchers at the Institute are delivering internationally renowned research every day.
  • Oslo University Hospital is the only hospital in Scandinavia accredited as a “Comprehensive Cancer Center”. The accreditation demands constant development of research, infrastructure and treatments.

Still a way to go

Things are still far from perfect. Almost everyday in the news, there are discussions about whether Norwegian cancer patients are offered the best cancer treatments. I believe we still have a way to go. In order to give better cancer treatments, we must heavily invest in the development of:

  • Molecular diagnostics
  • Cell and gene therapy
  • Precision medicine
  • The treatment of antibiotic resistance

Because of the success we have had so far with the Oslo Cancer Cluster Innovation Park and the need to strengthen cancer care further, we wish to expand the Oslo Cancer Cluster Innovation Park during the next five to seven years with close to 50 000 square metres. The first expansion will total 7 000 square metres. The planning scheme begins this year and the building itself will be located between the Innovation Park and the Institute for Cancer Research.

Enormous ambitions

The expansion of the Innovation Park is an important supplement to the plans on developing Oslo into Oslo Science City. We are also a living example of how public-private partnerships is the way to go in order to build a sustainable health industry, like the White Paper on the Health Industry has stated.

Norwegian cancer research is world class. The 15 companies in the Radforsk portfolio has spun out of this research. We have enormous ambitions to contribute even more to the development of the cancer treatments of tomorrow – to improve the lives of cancer patients all over the world.

As Prime Minister Erna Solberg said in her speech on 24 August 2015: “Smart minds and new ideas, students and professors, Norwegians and foreigners, founders and employees. Together for a common goal: to improve the treatment of the approximately 30 000 Norwegians that are diagnosed with cancer every year.”

That statement is still true today.

 


Oslo Cancer Cluster Innovasjonspark:
Kraftsenter for utvikling av kreftbehandling

Vi ønsker å utvide Oslo Cancer Cluster Innovasjonspark med nærmere 50.000 km² de neste fem til syv årene. Målet er å utvikle enda bedre kreftbehandling til det beste for kreftpasienter, i tett samarbeid med økosystemet rundt parken.

Av Jónas Einarsson, administrerende direktør i Radforsk og initiativtaker til Oslo Cancer Cluster, Oslo Cancer Cluster Inkubator og Oslo Cancer Cluster Innovasjonspark.

Den 24. august 2015 åpnet Statsminister Erna Solberg Oslo Cancer Cluster Innovasjonspark. I sin tale sa hun: «Oslo Cancer Cluster Innovasjonspark vil fylle en viktig rolle i utforming av fremtidens kreftbehandling.»

Og med det gikk startskuddet gikk for et unikt samarbeid mellom kreftforskere, klinikere, lærere, elever, forretningsutviklere og en rekke andre profesjoner som trengs for å utvikle morgendagens kreftbehandling.

Felles for alle oss som jobber her, er at vi har én visjon: Oslo Cancer Cluster Innovasjonspark og miljøet rundt med Radiumhospitalet og Institutt for Kreftforskning, skal være et internasjonalt kraftsenter for utvikling av kreftbehandling.

Fem år etter åpningen så lever vi ut denne visjonen hver dag. Jeg vil tørre å påstå at det vi har bidratt til er en suksess:

  • Oslo Cancer Cluster Incubator huser i dag ni oppstartsbedrifter, og vi jobber tett med syv andre som sitter andre steder og som det ikke er plass til
  • Oslo Cancer Cluster Innovasjonspark sine 24 private og offentlige leietakere ønsker mer plass da de stadig utvider sin virksomhet
  • Ullern videregående skole er en av de best søkte skolene i Oslo, og øker stadig elevtallet. Elevene på skolen får tilbud om å delta i det skolefaglige samarbeidet med Oslo Cancer Cluster, for å utdanne morgendagens forskere og entreprenører. Høsten 2019 startet Forskerlinja, et unikt tilbud til skoleelever i Oslo om fordypning i biomedisinske fag

Dette er bare inne i Innovasjonsparken. I området rundt oss skjer det unike ting som endrer måten pasienter med kreft blir behandlet på om få år:

  • I 2023 åpner det nye klinikkbygget på Radiumhospitalet med et spesialisert protonsenter
  • Institutt for Kreftforskning blir stadig videreutviklet under kyndig ledelse av professor Kjetil Taskén. De dyktige forskerne ved instituttet leverer daglig internasjonalt, anerkjent forskning
  • Oslo universitetssykehus er som eneste sykehus i Skandinavia akkreditert som et «Komplett kreftsenter», «Comprehensive Cancer Center». Akkrediteringen krever konstant utvikling av forskning, infrastruktur og behandling

Likevel er ikke tingenes tilstand rosenrød. I media kan vi nesten daglig lese diskusjoner om hvorvidt kreftbehandlingen pasienter i Norge tilbys er den beste. Min påstand er at vi har mye å gå på. For å gi bedre kreftbehandling må vi satse tungt på å utvikle:

  • Molekylær diagnostikk
  • Celle- og genterapi
  • Presisjonsmedisin
  • Behandling av antibiotikaresistens

På bakgrunn av den suksessen vi har hatt med Oslo Cancer Cluster Innovasjonspark så langt, og behovet for å styrke kreftomsorgen ytterligere, ønsker vi de neste fem til syv årene å utvide Oslo Innovasjonsparken med nær 50.000 km². Den første utvidelsen vil være på 7000 km². Prosjekteringen starter i år, og selve bygget vil ligge mellom Innovasjonsparken og Institutt for Kreftforskning.

Utvidelsen av Innovasjonsparken er et viktig tilskudd til planene om å utvikle Oslo som en kunnskapshovedstad, Oslo Science City. Vi er i tillegg et levende eksempel på at privat-offentlig samarbeid er veien å gå for å bygge en bærekraftig helsenæring, slik Stortingsmeldingen om helsenæring slår fast.

Norsk kreftforskning er i verdensklasse. Våre 15 bedrifter i Radforsk-porteføljen er spunnet ut av denne forskningen. Vi har enorme ambisjoner om at vi kan bidra enda mer til utviklingen av morgendagens kreftbehandling – til det beste for kreftpasienter over hele verden.

Som Statsminister Erna Solberg sa i sin tale den 24. august 2015: «Kloke hoder og nye ideer, studenter og professorer, nordmenn og utlendinger, gründere og ansatte. Samlet med ett felles mål: å bedre behandlingen til de om lag 30.000 nordmenn som blir diagnostisert med kreft hvert år.»

Det er like sant i dag.

Oslo Cancer Cluster Innovasjonspark med Institutt for Kreftforskning, Oslo Universitetsykehus, til venstre. Foto: Christian Tandberg/Oslo Cancer Cluster

Oslo Cancer Cluster Innovasjonspark med ny eierstruktur

Oslo Cancer Cluster Innovasjonspark

Please scroll down for a version of this article in English.

Dette er endringene i eierstrukturen for Oslo Cancer Cluster (OCC) Innovasjonspark og OCCI Holding AS i begynnelsen av 2020.

OCC Innovasjonspark har siden starten vært eid av Utstillingsplassen Eiendom AS (UPL), Industrifinans OCCI AS, Siva Eiendom, Oslo Cancer Cluster, Radiumhospitalets Legat for Kreftforskning og OBOS Eiendom.

OBOS solgte sin eierandel til øvrige eiere tidligere i 2019. I en ny transaksjon 13. januar 2020 solgte UPL og Industrifinans OCCI AS sine aksjer til en ny eier, OCCI Invest AS. I samme transaksjon har Oslo Cancer Cluster solgt en mindre prosentandel.

Et kraftsenter innen kreft

OCC Innovasjonspark ligger på Montebello i Oslo ved siden av Oslo Universitetssykehus Radiumhospitalet og Institutt for kreftforskning. Parken åpnet offisielt i august 2015.

Innovasjonsparken huser mange bedrifter som utvikler kreftbehandlinger og diagnostikk, deler av Oslo Universitetssykehus, Kreftregisteret, Radforsk, Oslo Cancer Cluster Incubator, Oslo Cancer Cluster og Ullern videregående skole.

UPL og Industrifinans OCCI AS har sammen med de øvrige eierne, gjennom sitt eierskap i OCCI Holding AS, vært med på å utvikle OCC Innovasjonspark til et kraftsenter innen kreft. UPL har også hatt prosjektansvar og ansvar for å forvalte eiendommen.

– Vi er svært takknemlig for de investorene som investerte i et risikoprosjekt, som var nytt og banebrytende før det åpnet, sier Jónas Einarsson, styremedlem i OCC Innovasjonspark og Oslo Cancer Cluster.

Innovasjonsparken er i dag utleid til viktige samfunnsfunksjoner, og har blitt en naturlig del av et viktig økosystem for kreftforskning i Norge.

Gir stafettpinnen videre

Som en del av sin strategi, gir tidligere eiere nå stafettpinnen videre til nye og langsiktige eiere i OCCI Invest AS. Selskapet er eid av solide eiere, og det er etablert og forvaltet av Pareto Securities AS.

– Konseptet til innovasjonsparken utvikler vi videre – med nye langsiktige investorer. De kan vente seg mye av framtidig utvikling her, og jeg ser fram til å utvikle prosjektet videre med nye og gamle eiere, sier Einarsson.

Tron Sanderud, administrerende direktør i UPL, er også stolt av prosjektet. UPL vil fortsette som forvalter av eiendommen inntil videre.

Nytt bygg planlagt

Innovasjonsparken består i dag av ca. 36 000 kvm kontorer, laboratorier, møterom, auditorier, undersøkelsesrom og videregående skole for over 900 elever.

– Vi har planlagt å bygge nye 7 000-8 000 kvm i andre byggetrinn. Dette bygget vil bli utviklet med nye og spennende prosjekter i samarbeid mellom akademiske institusjoner og industrien. Vi planlegger å starte prosjekteringen av det nye bygget i løpet av 2020, forteller Einarsson.

Nye eierandeler i januar 2020

OCCI Invest AS: 53.7 %
SIVA Eiendom Holding AS: 40,7 %
Radiumhospitalets legat for kreftforskning: 4.6 %
Oslo Cancer Cluster: 1,0 %

 

Oslo Cancer Cluster Innovation Park gains new owners

The following changes are being made to the ownership of Oslo Cancer Cluster (OCC) Innovation Park and OCCI Holding AS as of the beginning of 2020.

OCC Innovation Park has since its opening been owned by Utstillingsplassen Eiendom AS (UPL), Industrifinans OCCI AS, Siva Eiendom, Oslo Cancer Cluster, Radiumhospitalets Legat for Kreftforskning and OBOS Eiendom.

OBOS sold their shares to the other owners earlier in 2019. In another transaction on 13 January 2020, UPL and Industrifinans OCCI AS sold their shares to a new owner, OCCI Invest AS. In the same transaction, Oslo Cancer Cluster has sold a smaller percentage of their shares.

A power centre in cancer

OCC Innovationpark is located in the Montebello area of Oslo, next to the Oslo University Hospital (Radiumhospitalet) and the Institute for Cancer Research. The park was officially opened in August 2015.

The Innovation Park houses many companies that develop cancer treatments and diagnostics, parts of Oslo University Hospital, the Cancer Registry of Norway, Radforsk, Oslo Cancer Cluster Incubator, Oslo Cancer Cluster and Ullern Upper Secondary School.

UPL and Industrifinans OCCI AS have together with the other owners, through their ownership in OCCI Holding AS, developed OCC Innovation Park to a power centre in cancer. UPL have also been responsible for projects and for managing the property.

“We are very thankful to the investors that invested in this risk project, which was new and ground-breaking before it opened,” said Jónas Einarsson, board member in OCC Innovation Park and Oslo Cancer Cluster.

The Innovation Park is today leased for important services to society and has become a natural part of an important ecosystem for cancer research in Norway.

Passing on the baton

As a part of their strategy, the former owners are now passing on the baton to new and long-term owners in OCCI Invest AS. The company is owned by solid owners and is established and managed by Pareto Securities.

“We are continuing to develop the concept of the Innovation Park – with new, long-term investors. They can expect a lot of future developments here and I look forward to develop this project further with new and current owners,” Einarsson said.

Tron Sanderud, CEO of UPL, is also proud of the project. UPL will continue as manager of the property.

New building planned

The Innovation Park today consists of approximately 36 000 square meters of offices, laboratories, meeting rooms, auditoriums, patient screening rooms and an upper secondary school with over 900 students.

“We have planned to build 7 000-8 000 square metres as part of the second construction phase. This new building will be developed with new and exciting projects in collaboration with academic institutions and the industry. We are planning to start the scheme for the new building during the course of 2020,” said Einarsson.

New shareholding as of January 2020

OCCI Invest AS: 53.7 %
SIVA Eiendom Holding AS: 40,7 %
Radiumhospitalets legat for kreftforskning: 4.6 %
Oslo Cancer Cluster: 1,0 %

 

Sign up to our monthly newsletter

Thermo Fisher Scientific Norway was one of many stops during the guided tours through Oslo Cancer Cluster Innovation Park for students of Ullern Upper Secondary School.

A peak into the cancer research world

ThermoFisher Scientific Norway lectures students at Ullern

Ullern Upper Secondary School is unique, because it shares its building with world-class cancer researchers. Last month, all new Ullern students got to experience this first-hand.

This year’s School Collaboration Days in Oslo Cancer Cluster Innovation Park were held right before the autumn holiday. All the first-year classes at Ullern Upper Secondary School were given a guided tour around the Innovation Park to get to know the companies that they share their everyday lives with.

The purpose of the School Collaboration Days is to give the first-year students at Ullern Upper Secondary School an understanding of what the different companies in the Innovation Park and departments of Oslo University Hospital do.

The common denominator for all of them is cancer and many are developing new cancer treatments. While the Cancer Registry of Norway are collecting statistics and doing cancer research, Sykehusapotekene (Southern and Eastern Norway Pharmaceutical Trust) produce chemotherapy and antibodies for patients that are admitted to The Norwegian Radium Hospital and the Department of Pathology (Oslo University Hospital) gives the cancer patients their diagnoses.

 

IN PICTURES

The student guided tours of Oslo Cancer Cluster Innovation Park

Jonas Einarsson lecturing to students at Ullern

True to tradition, Jónas Einarsson, CEO of the evergreen fund Radforsk, opened the School Collaboration Days in Kaare Norum auditorium with a common lecture. In this image, Einarsson is talking about the development of the Montebello area, which Oslo Cancer Cluster Innovation Park is a part of. The first Radium Hospital was opened in 1932 and the following year Ullern School was moved from Bestum to the same place that houses Oslo Cancer Cluster Innovation Park today.

 

Kreftregisteret lecturing to students at Ullern.

Elisabeth Jakobsen, Head of Communications of the Cancer Registry of Norway, tells the first year students about what they do and the risk factors for developing cancer. Also, she asked the students several questions about how to regulate the sales of tobacco, e-cigarettes and many other things.

 

Thor Audun Saga is the CEO of Syklotronsenteret (“the Norwegian medical cyclotron centre”). He told the students about what they do, what a cyclotron is and how they use cyclotrons to develop cancer diagnostics.

 

ThermoFisher Scientific Norway lectures students at Ullern

The management of Thermo Fisher Scientific Norway are also housed in the Oslo Cancer Cluster Innovation Park. They told the students about the Norwegian invention called “Ugelstadkulene”. This is both the starting point for million of diagnostic tests across the world and revolutionary (CAR T) cancer treatments, 45 years after they were invented.

 

Students guided through the Oslo Cancer Cluster Incubator Laboratory

The tour was ended with a walk through the laboratory of the Oslo Cancer Cluster Incubator. The students were given an inside look at the work done and instruments used by the cancer researchers in the lab. This area is only one or two floors above their regular class rooms. The student could see first-hand the opportunities there are in pursuing a career in research, entrepreneurship and innovation.

10th Cancer Crosslinks: Precision Treatment Reviewed

For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data.

 

Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a closer look at developments over the last decade, and highlighted “Precision Treatment: Exploiting Recent Advances – Fast and Furious?”.

Weber Gazed into the Crystal Ball
The leading immunotherapy expert professor Jeffrey S. Weber visited Cancer Crosslinks for a second time. Weber has worked with immunotherapy for 30 years.  He provided an overview on recent advances. He shared new data showing that the combination of a certain vaccine and a type of immunotherapy called Checkpoint inhibitors, are especially effective against cancer. He also gazed into the crystal ball and made predictions on the future of cancer treatment. Weber is optimistic and thinks there are several promising combinations of precision treatments on the horizon.  He believes we can hope for a survival rate of 70-80 percent for people with certain cancers.

A Fiber Diet is Recommendable
Professor Laure Bindels from Belgium explored the theme of Microbiome, Cancer and Cachexia. Diet can be an important tool to fight cancer and cancer symptoms. Her research on mice indicates that changing to a fiber-rich diet can prevent undernourishment and increase the survival rate for cancer patients.

Hege Russnes and Anne Hansen Ree introduced us to the MetAction project where they conduct extended personal diagnostic testing to give cancer patients better and more effective treatment.

From the USA, we were introduced to precision treatment of gynecological cancer from Douglas A. Levine.  He was followed by Professor Andreas Engert, who raised the hot topic of establishing joint European guidelines for treatment across Europe for hematological cancer.

A Big Maybe to Big Data
The last speakers of the day where Assistant Professor Marcela Maus from Harvard Medical School, and Elisabeth Wik and Marc Vaudel from the University of Bergen. Professor Maus explained the use of CAR T- cells in cancer treatment. CAR-T Cells are T-cells with modified receptors to make them more effective against certain diseases, in this case cancer.

Elisabeth Wik and Marc Vaudel, with backgrounds from cancer research and computer science, discussed the use of big data in cancer research and treatment. Will big data revolutionize cancer treatment? The answer is maybe. We don’t know yet, it has potential.  We need to continue exploration, research, and collaboration to find out.

Download the Presentations
For those of you who missed the event or would like to revisit:

You may watch most of the presentations here.

You can download presentations from the meeting here:

Opening and Welcome with Jutta Heix from Oslo Cancer Cluster and Anne Kjersti Fahlvik, Executive Director Innovation, The Norwegian Research Council.

Jeffrey S. Weber. Opening Keynote: Cancer Immunotherapy – The Journey So Far and Where We Are Heading.
Jeffrey S. Weber, Professor, Deputy Director and Co-Director, Melanoma Program, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, USA.

Laure Bindels. International Keynote: The Microbiome, Cancer and Cachexia.
Laure Bindels, Louvain Drug Research Institute, Université catholique de Louvain, Belgium.

Hege G. Russnes and Anne Hansen ReeFrom Feasibility to Utility in Precision Medicine – Experiences from the first Norwegian Study of NGS-Based Therapy Decisions in Advanced Cancer.
Hege G. Russnes, Senior Consultant and Researcher, Oslo University Hospital, Norwegian Radium Hospital, Norway
Anne Hansen Ree, Professor, Akershus University Hospital, University of Oslo, Norway

Douglas A. Levine. International Keynote: Precision Medicine for Gynecologic Cancers – Opportunities and Obstacles.
Douglas A. Levine, Professor, Director of Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center & Head, Gynecology Research Laboratory, NYU Langone Medical Center, New York, USA.

Andreas Engert. International Keynote: Roadmap for European Hematology Research and Hodgkin Lymphoma: (Immuno)therapy, Late Effects and the Way Forward.
Andreas Engert, Professor for Internal Medicine, Hematology and Oncology, University Hospital of Cologne, Germany.

Marcela V. Maus. International Keynote: The Next Generation of Engineered T-cells for Immunotherapy of Hematological and Solid Tumors.
Marcela V. Maus, Assistant Professor, Harvard Medical School & Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, Boston, USA.

Marc Vaudel  and Elisabeth Wik: Making Sense of Big Data for Oncology Patients – Vision and Reality
Marc Vaudel, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital and KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway
Elisabeth Wik, Centre for Cancer Biomarkers, University of Bergen and Department of Pathology, Haukeland University Hospital, Norway

Giving Tuesday Crowdfunds for Cancer

You have probably heard of Black Friday. Now introducing Giving Tuesday: A day all about giving rather than buying. Eight Norwegian YouTubers have chosen to crowdfund on behalf of The Norwegian Cancer Society as part of Giving Tuesday. Raising money for cancer research and cancer patient care. A week before the big day five of them visited Oslo Cancer Cluster.

 

Tuesday the 28th of November, conveniently a couple of days after the shopping bonanza of Black Friday, is Giving Tuesday. It’s an international event. Started in 2012 by the 92nd Street Y and the United Nations Foundation as a response to Black Friday and commercialization and consumerism in the post-Thanksgiving season.

Live Social Media Broadcast
On the day the Norwegian youTubers are staging a broadcast marathon on social media. At DnB Headquarters (Bjørvika) they all come together for a live broadcast so everybody can follow the crowdfunding and view their videos during Giving Tuesday.  And there are a lot of them. 10 other charities are being crowdfunded on the day with youTubers raising money on their behalf.

Learn more about what’s happening here.

Learning About Cancer Research
The last couple of weeks the youtubers funding for The Norwegian Cancer Society have learned about cancer research and the fight against cancer. They have visited the Society’s new Science Center learning about the history of the disease and afterwards they spent a day getting updated on current cancer research at Oslo Cancer Cluster.

At Ullern Innovation Park, the home of Oslo Cancer Cluster, they got to see researchers in action and learned about the recent advances in cancer research. How researchers now are trying to trigger the immune system in the fight against cancer and how we are getting better at producing medicines that target cancer tumors directly. They also got see how research and innovation merges together with education at the Innovation Park. Here researchers, Bio Businesses and Ullern Upper Secondary School share the same building and cooperate.  Learn more about this unique cooperation.

With this new knowledge on cancer they are well prepared to crowdfund a lot of money for The Norwegian Cancer Society and cancer research!

About the YouTubers
Christoffer Ødegård (17) Specializes in FIFA. Playing live games on youTube.

Emil Saglien (15) Also into football. Actually, about his life, but his life seems to be football.

Sara Høydahl (19) Vlogs about many things, but has had special success with a Friday special on murder mysteries!

Truls Valsgård (23), Truls is a full time youtuber. Produces videos daily about his own life.

Tuva Robsrud (16) From Bærum and vlogs about fashion and make up.

 

International press event created attention all over Europe

Early September Oslo Cancer Cluster hosted an international press event with our member Abbvie. Over 20 journalists from all over Europe came to the Oslo Cancer Cluster Incubator and Innovatiion Park to learn more about the latest technological and scientific developments within cancer research.

 

The journalists attended a full day meeting at the Innovation Park which included a lab session with Ullern High School students and researchers at the Cell Therapy Lab, whom showed them how cells are programmed to kill cancer cells. Gunnar Sæter, Head of the Cancer Institute, introduced the journalists to the topic of precision medicine in oncology with Oslo Cancer Cluster members SAS and IBM demonstrating the latest developments within data collection and analysis. Giske Ursin, Director of  Cancer Registry Norway, explained how the unique health data we have in Norway provides a large unused potential within oncology.

 

The journalist also got to meet Deborah Simms, journalist and cancer survivor and her doctor, John Gribben from the Barts Cancer Institute. They explained the role of collaboration in the diagnostics and treatment of patients with unmet need.

 

You can see the invitation video for the event here:

See the video from the event made by students at Ullern High School here:

More about Deborah Simms and her patient journey here:

News stories related to the event:

Fantastic opening of the Oslo Cancer Cluster Innovation Park

Oslo Cancer Cluster Innovation Park´s grand opening on August 24th became a very special day: More than 290 invited guests celebrated the initiators Jónas Einarsson and Kaare Norum for turning the radical idea of an oncology innovation park integrating a high school into reality.

 

In his speech, Jónas Einarsson told the intriguing history of cancer treatment and research in Norway since the early 1900s; driven by visionary men and funding from the people. A joint effort that has made cancer research one of the strongest areas within medicine and health research in Norway.

Einarsson also used the opportunity to thank some of the truly vital players in the realization of the Innovation Park: Tron Sanderud from Utstillingsplassen Eiendom, Toril Mølmen, former Head of Innovation Norways office in Oslo, Jan Vincents Johannesen, CEO Radium Foundation, Espen Susegg in SIVA and Pål Riis, former principal of Ullern High School.

 

OBOS will sponsor lab
The Opening Celebration started with the fantastic news from Arne Baumann, Chairman of the Board of the Innovation Park, that OBOS, apart from being one of the largest owners, also will sponsor the lab in the Oslo Cancer Cluster Incubator with 4MNOK.

Together with a 2 MNOK donation from the Radium Foundation the Incubator may offer state-of-the-art facilities to the companies and researchers renting here.

 

Erna tried out life as cancer researcher
Erna Solberg, Prime Minister of Norway surprised Mr. Einarsson with inviting him on stage cutting an orange bond to mark the official opening. In her speech, Solberg, said that health industry is an industry with double return in from of the values it creates for the society and patients in developing new treatments as well as developing jobs and value. She also said that the Innovation Park will play a major role in the development of the cancer treatment of the future.

After her speech, Einarsson guided the Prime Minister and the media on a short tour of the Innovation Park where Solberg ended up in the Incubator lab where she tried out the PCI-technology to kill cancer cells.

 

Erna_lab

Photo credit both pictures: Gunnar Kopperud.

Below we have gathered some of the media coverage, both nationally and abroad. We will also publish some videos from the opening later on. 

 

Media coverage:

TV:

Digital:

 

International coverage:

 

Grand Opening of the Oslo Cancer Cluster Innovation Park

When the Prime Minister opens the Oslo Cancer Cluster innovation Park at Montebello in August, the founder Jónas Einarsson are already planning the next steps for the Radium Hospital Innovation Campus.

Monday August 24th is the official opening of the Oslo Cancer Cluster Innovation Park. This unique project is built on private enthusiasm and builds on the long history of cancer research and treatment performed at the Norwegian Radium Hospital. The Innovation Park includes Ullern High School, The Cancer Registry of Norway, Oslo Cancer Cluster Incubator, and Institute for Medical Informatics and Pathology at Oslo University Hospital – as well as global biopharmaceutical and biotech companies.

Integrated high school
Early 2000, Jónas Einarsson, CEO at the Radium Hospital Research Foundation, and Kaare Norum, former principal of the University of Oslo, realized that a natural cluster for cancer research, development and innovation emerged in the Oslo-area. Together they established Oslo Cancer Cluster, a research and industry cluster within cancer.

They soon realized that the milieu needed a physical innovation center for collaboration, innovation and networking across disciplines. The idea of an innovation park were born, optimally placed right next to the Norwegian Radium Hospital and with Ullern High School as an integrated part to attract and develop talents to cancer R&D and entrepreneurship.

“As a former principal and a man with education as his focus, Kaare Norum came up with the idea to integrate Ullern High School,” says Einarsson. “Ullern and principal at that time, Paal Riis, was very positive from day one, “Einarsson explains, “The collaboration started in 2009 and is expanding every year, and we look forward to being located in the same building.”

All ready for next steps
Oslo Cancer Cluster Innovation Park aims to create one of Europe’s leading centers for education, research and industry in cancer. “By building the park right next to the hospital and Institute for cancer research, the value chain from basic research to industry is brought together at one place: The Radium Hospital Innovation Campus.

Einarsson is already planning the next steps to strengthen the campus further; “We will expand with more buildings and facilities,” he says. “The need for a new clinic building at the Radium Hospital is urgent, and the Oslo-area lack a center for proton treatment. We have investors and drawings in place already”.

Unique project
“We are honoured to have Prime Minister Erna Solberg opening Oslo Cancer Cluster Innovation Park. Governing Mayor of Oslo, Stian Berger Røsland and Head of Oslo University Hospital, Bjorn Erikstein are also part of this celebration “ says  Arne Baumann, Chairman of the Board of the Innovation Park. “We look forward to show them the uniqueness of this project; the park integrates education, excellent research and innovations, and represents a real opportunity to make biotech and health research a new Norwegian industry. Oslo Cancer Cluster Innovation Park is really one of a kind,” Baumann states.

 

Facts:

Oslo Cancer Cluster Innovation Park AS

Total space: 36 000 m²

Tenants: Oslo university Hospital, The Institute for Cancer Genetics and Informatics, Norwegian Cancer registry, Oslo Cancer Cluster SA, Oslo Cancer Cluster Incubator AS, The Norwegian Radium Hospital Research Foundation, The Oslo Hospital Pharmacy, Ullern High School, global pharma companies, Norwegian biotech companies.

Opens officialy August 24.th 2015 by the Prime Minister of Norway, Erna Solberg.

Great Kick-off for the Oslo Cancer Cluster Innovation Park

Oslo Cancer Cluster, in collaboration with Radiumhospitalets Legater, invite members and collaborators to the annual Oslo Cancer Cluster R&D Summer Meeting on Wednesday August 20th at the Auditorium , Institute of Cancer Research.

Download program and register here

The summer meeting will kick off the Oslo Cancer Cluster Innovation Park, and for the first time it will be possible to go inside the Innovation Park. As usual, we also present the new members of the cluster; Teva Scandinavia,
Smartfish, Pharmalink,  NorChip, Oncoimmunity  and SFF – Centre for Cancer Biomarkers, University of Bergen.

Program

–15:00: Registration & coffee

15:00– 15:20: “Welcome – update on main projects”
– Ketil Widerberg, General Manager of Oslo Cancer Cluster

15:20–15:40: “The Radium Hospital Innovation Campus”
– Jan Vincent Johannessen, CEO Radium Hospital Foundation

15:40–16:00: “Ullern High School – Spring 2015”
– Esther Eriksen, Ullern High School

16:00–16:20: “Oslo Cancer Cluster Innovation Park”
– Jónas Einarsson, CEO of The Radium Hospital Research Foundation, founder of the Innovation Park

16:40–17:00: Refreshments

17:00–18:00: “New Kids on the Block” – presentations from new members;
• Teva Scandinavia, Asker
• Smartfish, Oslo
• Pharmalink, Stockholm
• NorChip, Hurum
• Oncoimmunity, Oslo
• SFF – Centre for Cancer Biomarkers, Bergen

18:00: Summer networking with exclusive group tours “inside” the Oslo Cancer Cluster Innovation Park guided by Skanska

 

 

Great Kick-off for Oslo Cancer Cluster Innovation Park

More than 170 people kicked-off the Oslo Cancer Cluster Innovation Parkat the annual Oslo Cancer Cluster Summer Meeting. The Innovation park opens in less than a year, and for the first time participants from the cluster could come in side the Park.

 

 

Program

–15:00: Registration & coffee

15:00– 15:20: “Welcome – update on main projects”
– Ketil Widerberg, General Manager of Oslo Cancer Cluster

15:20–15:40: “The Radium Hospital Innovation Campus”
– Jan Vincent Johannessen, CEO Radium Hospital Foundation

15:40–16:00: “Ullern High School – Spring 2015”
– Esther Eriksen, Ullern High School

16:00–16:20: “Oslo Cancer Cluster Innovation Park”
– Jónas Einarsson, CEO of The Radium Hospital Research Foundation, founder of the Innovation Park

16:40–17:00: Refreshments

17:00–18:00: “New Kids on the Block” – presentations from new members;
• Teva Scandinavia, Asker
• Smartfish, Oslo
• Pharmalink, Stockholm
• NorChip, Hurum
• Oncoimmunity, Oslo
• SFF – Centre for Cancer Biomarkers, Bergen

18:00: Summer networking with exclusive group tours “inside” the Oslo Cancer Cluster Innovation Park guided by Skanska